What are the benefits of influenza (flu) and respiratory syncytial virus (RSV) vaccination in elderly patients (age ≥ 65 years)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Benefits of Flu and RSV Vaccination in Elderly Patients

Elderly patients aged ≥65 years should receive both influenza and RSV vaccines, as these vaccinations significantly reduce mortality, hospitalizations, ICU admissions, and cardiovascular complications while preserving functional independence.

Influenza Vaccination Benefits

Mortality and Hospitalization Reduction

Influenza vaccination in community-dwelling adults aged ≥65 years provides 48% reduction in mortality risk and 27% reduction in hospitalization risk 1. Approximately 90% of flu-related deaths occur in older people, making vaccination a critical component of healthy aging 1.

Hospital Outcomes

For hospitalized older patients who were previously vaccinated, outcomes are substantially better with:

  • Lower ICU admission rates
  • Reduced need for invasive ventilation
  • Decreased bacterial pneumonia rates 1

Cardiovascular Protection

Influenza vaccination is associated with lower risk of hospitalization for heart disease in community-dwelling older adults, with convincing strength of evidence from cohort studies 2. This cardiovascular benefit extends beyond respiratory protection and represents a major mortality-reducing mechanism 3.

High-Dose Vaccine Superiority

High-dose influenza vaccines consistently outperform standard-dose vaccines in older adults 1. Studies demonstrate:

  • Reduced respiratory-related hospital admissions (3.4% vs 3.9% over 6 months in nursing home residents)
  • Lower mortality (17.1% vs 18.3%)
  • Decreased risk of pneumonia, cardiorespiratory illnesses, and hospitalization

The evidence supports high-dose vaccines regardless of age, comorbidities, frailty, or prior vaccination history 1.

RSV Vaccination Benefits

Disease Prevention and Severe Outcomes

RSV vaccines demonstrate 75-82% effectiveness against RSV-associated hospitalization in adults aged ≥60 years during the first season post-vaccination 4. The efficacy extends across multiple seasons:

  • RSVPreF3: maintained efficacy for at least 3 seasons
  • RSVpreF: maintained efficacy for at least 2 seasons 4

High-Risk Populations

RSV vaccination is particularly beneficial for adults with chronic conditions. Vaccine effectiveness remains high even in:

  • Immunocompromised individuals: 73% effectiveness 4
  • End-stage renal disease patients: 72-83% effectiveness 4
  • Those with chronic cardiopulmonary conditions: 63.2% efficacy against severe disease 4

Cardiovascular and Functional Benefits

RSV vaccines are associated with:

  • Lower incidence of cardiorespiratory hospitalization and stroke 3
  • Potential preservation of functional status and independence 5, 6
  • Reduced risk of ICU admission and death 4

Important caveat: While cardiovascular protection is biologically plausible and supported by observational data, it has not been independently demonstrated in randomized trials specifically for RSV vaccines 6.

Real-World Impact

During the 2023-2024 season in the US, RSV vaccinations averted:

  • 18,326 emergency department visits
  • 23,630 hospitalizations
  • 1,930 deaths 7

Practical Implementation Algorithm

Who Should Be Vaccinated

Influenza (annually):

  • All adults ≥65 years
  • Use high-dose or adjuvanted formulations preferentially 1

RSV (single dose):

  • Strongly recommended 4:

    • All adults ≥75 years
    • Adults ≥60 years with chronic conditions (COPD, asthma, heart failure, coronary artery disease, diabetes, chronic kidney disease, chronic liver disease, immunocompromise)
    • Adults ≥50 years residing in nursing homes or with frailty/dementia
    • Adults ≥18 years on dialysis, home oxygen, or post-transplant
  • May be considered:

    • All adults ≥60 years without specific risk factors 4

Timing

  • RSV: Preferably September-November 4
  • Influenza: During flu season (typically October-November)
  • Both vaccines can be co-administered at different injection sites 4

Common Pitfalls to Avoid

  1. Don't restrict high-dose flu vaccines to nursing home residents only - immunosenescence affects all older adults, and limiting access raises ethical concerns 1

  2. Don't assume RSV is only for the "oldest old" - adults ≥60 years with chronic conditions have comparable disease burden to those ≥75 years 4, 8

  3. Be aware of numerically lower antibody titers with co-administration - when RSV and flu vaccines are given together, slightly lower immune responses are observed compared to separate administration, though clinical relevance is unknown 4

  4. Monitor for rare adverse events - while both vaccines have favorable safety profiles, ongoing surveillance for events like Guillain-Barré syndrome continues 8

  5. Don't overlook functional outcomes - vaccination benefits extend beyond infection prevention to preserving independence and quality of life, though these are rarely assessed in trials 5

Cost-Effectiveness

Influenza vaccination is highly cost-effective, reducing healthcare costs by 2.75% and years of life lost by over 50% 1. The WHO considers it the main preventive strategy in older persons and views it as critical for healthy aging 1.

References

Research

[Beyond infection prevention: The indirect benefits of vaccination in older adults].

Geriatrie et psychologie neuropsychiatrie du vieillissement, 2026

Related Questions

Which of the following statements is true: all three respiratory syncytial virus (RSV) vaccines are indicated to prevent lower respiratory tract disease in individuals aged 60 years and older, or all three RSV vaccines are indicated to prevent lower respiratory tract disease in high‑risk individuals aged 18–59 years?
What are the age‑specific vaccination recommendations for patients with cardiac disease?
Is there evidence that pneumococcal vaccines (PCV13 and PPSV23) prevent cardiovascular disease?
Should adults aged 65 years and older be recommended to receive the respiratory syncytial virus (RSV) vaccine, and which dosing regimen is appropriate?
Should a 46-year-old man with chronic respiratory disease who is on continuous home oxygen and lives in a group home receive respiratory syncytial virus (RSV) vaccination?
What is the maximum recommended dose of hydroxyzine for an adult using it as a sleep aid?
When is linezolid indicated for staphylococcal infections, and what are the recommended dosing and monitoring guidelines?
What are the criteria for selecting carotid endarterectomy versus carotid artery stenting and the recommended medical therapy for patients with significant carotid stenosis?
In a patient with resolved hepatitis B infection and documented immunity (HBsAg negative, anti‑HBc IgG positive, anti‑HBs positive), is routine long‑term follow‑up and surveillance laboratory testing required?
What does TCAR (TransCarotid Artery Revascularization) stand for in relation to carotid stenting?
Which contraceptive method provides the highest efficacy with minimal side effects, preserves female fertility, and allows rapid return to fertility after 1–2 years of use, given that Implanon (etonogestrel implant) causes irregular/heavy bleeding, combined oral contraceptives cannot be used long term, depot medroxyprogesterone acetate (DMPA) causes osteoporosis and amenorrhea, and the levonorgestrel intrauterine system (Mirena) causes irregular/heavy bleeding?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.